"I would frame it as, as research focuses on what the biology or the chemistry of a molecule requires, manufacturing can be responsive to that trial and error to be able to accelerate the molecule once we land on the particular process."
Small-Molecule Agility Can Inform Biologics Manufacturing, Says Merck
Merck's Dr Dave Maraldo explains that small-molecule platform agility and flexible conjugation capacity can help biologics manufacturing respond to research needs.
In the second segment of an interview with BioPharm International®,
Dr Maraldo says small-molecule manufacturing offers lessons in platform agility for biologics.
How can capital investment keep bioconjugation flexible?
Asked whether this investment strategy amounts to a trial-and-error approach, Dr Maraldo says that it links to core technologies, and conjugation is key know-how. Many methods exist, he emphasizes. Manufacturers can conjugate in a stainless-steel reactor or in a
"I would frame it as, as research focuses on what the biology or the chemistry of a molecule requires, manufacturing can be responsive to that trial and error to be able to accelerate the molecule once we land on the particular process," he explains.
Some capabilities already overlap between the 2 worlds, he says. Many small-molecule programs, and the wider industry, use enzymes, and producing an enzyme involves an Escherichia coli fermentation, a form of cell culture. Dr Maraldo points out that those capabilities are quite analogous between small molecules and large molecules. Those shared capabilities show where learning can transfer, he adds.
Learn more from
About the speaker
Dave Maraldo, PhD, Executive Vice President and President, Merck Manufacturing Division
Dr Maraldo has responsibility for Merck’s worldwide human health manufacturing and supply operations across a global network of sites for pharmaceuticals, vaccines and biologics. Since joining the company as a project engineer in 1999, he progressed through a range of leadership roles across manufacturing, technical operations, commercialization and integrated development and supply. Building on that foundation, he led global biologics operations from 2022- 2025 and most recently served as senior vice president of human health manufacturing. Dr Maraldo earned his PhD and master of chemical engineering degrees from Drexel University, an MBA degree from Lehigh University and a bachelor of chemical engineering degree from Widener University.
Related to this article









